Boston Scientific (NYSE:BSX) Releases FY 2025 Earnings Guidance

Boston Scientific (NYSE:BSX) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 2.870-2.940 for the period, compared to the consensus estimate of 2.880. The company issued revenue guidance of $19.3 billion-$19.6 billion, compared to the consensus revenue estimate of $19.5 billion. Boston Scientific also updated its Q2 2025 guidance to 0.710-0.730 EPS.

Analysts Set New Price Targets

A number of brokerages have commented on BSX. BTIG Research reissued a “buy” rating and issued a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, April 23rd. Argus set a $130.00 target price on shares of Boston Scientific in a research note on Tuesday, February 18th. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, April 29th. Robert W. Baird raised their price objective on shares of Boston Scientific from $115.00 to $120.00 and gave the company an “outperform” rating in a research note on Thursday, April 24th. Finally, Barclays raised their target price on shares of Boston Scientific from $118.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, April 25th. Twenty-one research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Boston Scientific currently has an average rating of “Buy” and an average price target of $116.00.

Boston Scientific Stock Performance

Shares of BSX opened at $99.38 on Thursday. Boston Scientific has a 52-week low of $71.88 and a 52-week high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $147.03 billion, a PE ratio of 79.50, a P/E/G ratio of 2.79 and a beta of 0.68. The firm has a 50-day moving average price of $100.70 and a 200 day moving average price of $98.55.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The company had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same period in the prior year, the company earned $0.56 EPS. Boston Scientific’s revenue was up 20.9% on a year-over-year basis. On average, sell-side analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the company’s stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the completion of the sale, the chief executive officer now directly owns 1,535,706 shares of the company’s stock, valued at approximately $157,379,150.88. This represents a 9.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP John Bradley Sorenson sold 4,572 shares of the company’s stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the sale, the executive vice president now directly owns 18,705 shares of the company’s stock, valued at $1,955,420.70. This represents a 19.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 411,970 shares of company stock valued at $42,406,693. 0.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

A hedge fund recently raised its stake in Boston Scientific stock. Brighton Jones LLC grew its holdings in Boston Scientific Co. (NYSE:BSX) by 0.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,376 shares of the medical equipment provider’s stock after purchasing an additional 226 shares during the period. Brighton Jones LLC’s holdings in Boston Scientific were worth $2,445,000 as of its most recent SEC filing. 89.07% of the stock is currently owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.